BioArctic AB (publ)
BioArctic AB (publ) (BRCTF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
brctf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for BioArctic AB (publ) (BRCTF) measures how much investors pay for each dollar of the company's trailing earnings. BRCTF's current PE ratio of 122.21x is calculated by dividing its stock price of $35.00 by its TTM earnings per share of $2.41. −65.6% discount vs 5Y avg 355.1x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 7 fiscal years · Front-end computedMinQ1 · 25%260.4x
MedianQ3 · 75%4010.4x
Max
At 122.21x, BRCTF's current P/E is within its average historical range over the past 7 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BioArctic AB (publ)You BRCTF | $3.1B | 122.21x | +359.2% | $2.41 |
 Fagron N.V. ARSUF | $2.0B | 16.06x | -39.6% | $1.25 |
 Dermapharm Holding SE DMPHF | $2.9B | 13.70x | -48.5% | $2.46 |
 Genus plc GENSF | $2.3B | 64.70x | +143.1% | $0.29 |
 HBM Holdings Limited HBMHF | $2.1B | 21.81x | -18.1% | $0.12 |
 Hisamitsu Pharmaceutical Co., Inc. HTSUF | $2.0B | 16.80x | -36.9% | $269.34 |
 Mesoblast Limited MEOBF | $2.0B | N/A | — | -$0.08 |
Industry Average 5 peers with valid PE | — | 26.61x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 27.80x | $11.52 | — | |
2024-12-31 FY2024 | — | $-2.00 | — | |
2023-12-31 FY2023 | 104.75x | $2.59 | — | |
2022-12-31 FY2022 | — | $-0.13 | — | |
2021-12-31 FY2021 | — | $-1.36 | — | |
2020-12-31 FY2020 | — | $-0.78 | — | |
2019-12-31 FY2019 | 260.39x | $1.00 | +355.3% | |
2018-12-31 FY2018 | 57.19x | $4.33 | -95.7% | |
2017-12-31 FY2017 | 1325.16x | $0.17 | +241.4% | |
2016-12-31 FY2016 | 388.14x | $0.65 | -90.3% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BioArctic AB (publ) (BRCTF) measures how much investors pay for each dollar of the company's trailing earnings. BRCTF's current PE ratio of 122.21x is calculated by dividing its stock price of $35.00 by its TTM earnings per share of $2.41.
Frequently asked questions
BRCTF pe ratio · 6 questionsBRCTF's current PE ratio is 122.21x as of 2026-06-09, based on a stock price of $35.00 and TTM EPS of $2.41. Data sourced from Financial Modeling Prep via BRCTF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BioArctic AB (publ) SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09